<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00600509</url>
  </required_header>
  <id_info>
    <org_study_id>N165</org_study_id>
    <nct_id>NCT00600509</nct_id>
  </id_info>
  <brief_title>Bridging Study of L059 (Levetiracetam) in Patients With Epilepsy by Double Blind Method</brief_title>
  <official_title>Bridging Study of L059(Levetiracetam) in Patients With Epilepsy by Double Blind Method</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>UCB Japan Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Double-blind, randomized, placebo-controlled, multi center trial to evaluate the efficacy and
      safety of levetiracetam as adjunctive treatment in adult Japanese epileptic subjects with
      partial onset seizures.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2001</start_date>
  <completion_date type="Actual">July 2003</completion_date>
  <primary_completion_date type="Actual">July 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>partial onset seizure frequency per week</measure>
    <time_frame>collection of seizure count throughout the whole study (baseline and treatment periods)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>safety and tolerability</measure>
    <time_frame>safety and tolerability data were collected throughout the study period</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">216</enrollment>
  <condition>Epilepsy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levetiracetam</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  simple and/or complex partial seizures with or without secondary generalization, and
             first partial seizure &gt;= 2 years before selection visit;

          -  seizures classifiable according to the ILAE classification;

          -  minimum of 12 partial seizures per 12 weeks with a minimum of two partial seizures per
             4 weeks from the selection visit to the end of the baseline period ;

          -  exposed to two or more standard AEDs;

          -  taking up to three of the standard AEDs, at the initiation of the trial.

        Exclusion Criteria:

          -  medication influencing the CNS, except for medication taken for antiepileptic
             treatment;

          -  partial seizures uncountable due to clustering, including status epileptics, during
             the 3 months prior to the selection visit;

          -  history of cerebrovascular disease including transient ischemic attack (TIA) and
             progressive cerebral disorder or progressive neurological disorder;

          -  presence or history of any clinically significant allergic condition and complication
             or history of significant alcohol abuse or drug abuse in the past.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB Clinical Trial Call Center</last_name>
    <role>Study Director</role>
    <affiliation>+1 877 822 9493 (UCB)</affiliation>
  </overall_official>
  <link>
    <url>http://www.ucb.com/_up/ucb_com_patients/documents/N165_CSS_20080306.pdf</url>
    <description>Clinical Study Summary on UCB.com</description>
  </link>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 14, 2008</study_first_submitted>
  <study_first_submitted_qc>January 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2008</study_first_posted>
  <last_update_submitted>September 16, 2013</last_update_submitted>
  <last_update_submitted_qc>September 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 17, 2013</last_update_posted>
  <keyword>Levetiracetam</keyword>
  <keyword>Keppra</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etiracetam</mesh_term>
    <mesh_term>Piracetam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

